Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer?

Benzer Materyaller

• Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
  Yazar:: Imamura, Yusuke, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
  Yazar:: Shimizu, Yasuomi, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Crosstalk between the Androgen Receptor and β-Catenin in Castrate Resistant Prostate Cancer
  Yazar:: Wang, Gang, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
  Yazar:: Rathkopf, Dana, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
  Yazar:: Hirayama, Yukiyoshi, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)